RareCan’s NHS ethics approved BioResource enables us to collect, process, analyse and store our members tumour and blood samples.
We are not creating a ‘bio bank’, building up a big resource of stored samples. Rather we are focussed on providing tailored solutions to support our clients in both preclinical programmes (e.g. identification and validation of novel drug targets or biomarkers) and clinical programmes (e.g. screening for specific target mutations).
Empower Every Patient: Become a sponsor of our clinical trial matching service
Samples we work with
FFPE
- Slides
- Tissue microarrays
Fresh tissue
(Where histological diagnosis precedes surgical resection)
Blood
- ctDNA
Derived materials and data available
Digital images of H&E stained sections
Immunohistochemistry data
Extracted DNA
DNA sequencing data
Matched clinical data
Diagnosis & comorbidities
Longitudinal treatment & symptom data
Patient reported outcome measures (PROMS)
We founded RareCan because together we can increase treatment options for rare cancer patients.
We founded RareCan because together we can improve outcomes for people with rare cancers
We founded RareCan because together we can empower people with rare cancer
We founded RareCan because together we can increase the number of options and opportunities for people with rare cancers
Previous
Next
Our partners
We collaborate with partners across the healthcare system to support patients with rare cancers.
